Selective vascular disrupting therapy by lipid nanoparticle-mediated ...
Oct 1, 2025 · We investigated the effect of silencing FasL expression using cRGD-LNP (siFasL) on the efficacy of the combination therapy by substituting cRGD-LNP (siFasL) with an anti-FasL antibody …
Low-dose doxorubicin loaded extracellular vesicles combined Fas/FasL ...
Jul 20, 2024 · DOX performed its role on chemotherapy, and SNP successfully respond to the intracellular GSH to continuously generate nitric oxide (NO). The in situ-produced NO upregulated …
The Fas-FasL system: from apoptosis regulator to therapeutic
Mar 16, 2026 · Future therapeutic strategies will require selective targeting of disease-specific Fas/FasL-expressing cells to avoid damage to healthy tissues. Advances in targeted delivery platforms, …
Full article: Soluble Fas Ligand, an overlooked target of therapy in ...
Mar 2, 2026 · Therapies targeting this system are currently unavailable due to the complexity of the Fas/FasL pathway and the side effects associated with reduced apoptosis of cancer cells and the …
Mar 16, 2026 · Future therapeutic strategies will require selective targeting of disease-specific Fas/ FasL-expressing cells to avoid damage to healthy tissues. Advances in targeted delivery platforms, …
Evolutionary regulation of human Fas ligand (CD95L) by plasmin
Jul 1, 2025 · Here, we unexpectedly discover that, unlike chimpanzee and other primates, a critical embryonic development, immune homeostasis, and general cell-death regulator protein called Fas …
FAS mediates apoptosis, inflammation, and treatment of ... - Frontiers
Apr 22, 2025 · While FAS or FASL antibodies are primarily employed in treating autoimmune diseases and cancer, they also show promise against pathogen infections by either activating apoptosis in …
Mar 2, 2026 · The extracellular domain of human Fas and the Fc domain of human IgG1 was designed to specifically bind FasL, thus disrupting the Fas/FasL signal, and reducing tumor invasiveness (90).
Lipid nanoparticle delivery of Fas plasmid restores Fas expression to ...
Forced expression of Fas in tumor cells overcomes melanoma resistance to FasL-induced cell death in vitro. Lipid nanoparticle-encapsulated mouse Fas -encoding plasmid therapy eliminates Fas + tumor …
FasL gene therapy: a new therapeutic modality for head and
Mar 17, 2006 · In this study, we investigated the in vitro and in vivo efficacy of Fas ligand (FasL) gene therapy for the treatment of head and neck cancer.